NASDAQ, TSX: NVCN

VANCOUVER, Aug. 2, 2018/CNW/ - Neovasc, Inc. ('Neovasc' or the 'Company') (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the quarter and six months ended June 30, 2018and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, August 8, 2018.

Conference Call & Webcast

Wednesday, August 8th @ 4:30pm Eastern Time

Domestic:

888-254-3590

International:

323-994-2093

Passcode:

9226007

Webcast:

http://public.viavid.com/index.php?id=130206

Replays available through August 22nd:

Domestic:

844-512-2921

International:

412-317-6671

Conference ID:

9226007

About Neovasc Inc.
 Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ (the 'Reducer'), for the treatment of refractory angina, which is not currently commercially available in the United Statesand has been commercially available in Europesince 2015, and the Tiara™ (the 'Tiara'), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canadaand Europe. For more information, visit: www.neovasc.com.

SOURCE Neovasc Inc.

For further information: Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568

Attachments

  • Original document
  • Permalink

Disclaimer

Neovasc Inc. published this content on 02 August 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 August 2018 11:34:02 UTC